{"id":31820,"date":"2025-04-15T13:44:54","date_gmt":"2025-04-15T05:44:54","guid":{"rendered":"https:\/\/flcube.com\/?p=31820"},"modified":"2025-04-15T13:44:55","modified_gmt":"2025-04-15T05:44:55","slug":"boehringer-ingelheim-partners-with-cue-biopharma-to-advance-cue-501-for-autoimmune-diseases","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=31820","title":{"rendered":"Boehringer Ingelheim Partners with Cue Biopharma to Advance CUE-501 for Autoimmune Diseases"},"content":{"rendered":"\n

Germany’s Boehringer Ingelheim (BI) has entered into a strategic agreement with US-based Cue Biopharma, Inc. (NASDAQ: CUE<\/a>) to jointly develop and commercialize CUE-501, an innovative B cell depletion therapy for autoimmune diseases. This collaboration aims to advance a novel therapeutic approach that selectively targets B cells while engaging virus-specific memory killer T cells, potentially offering improved efficacy and safety.<\/p>\n\n\n\n

CUE-501: Mechanism and Innovation<\/strong>
CUE-501 is a preclinical candidate molecule designed to bind to a B cell-specific membrane protein while simultaneously engaging virus-specific memory killer T cells. This dual action enables the selective depletion of B cells and the modulation of autoimmune and inflammatory processes. The therapy represents a promising advancement over existing B cell-targeting approaches, which often lack the precision and safety profile of CUE-501.<\/p>\n\n\n\n

Collaboration Terms and Financials<\/strong>
Under the multi-year agreement, Cue Biopharma will receive an upfront payment of USD 12 million, along with research support payments. The company is also eligible to earn up to approximately USD 345 million in milestone-based payments tied to research, development, and commercialization outcomes. The collaboration includes provisions for expanding research into various B cell-targeting bispecifics, potentially broadening the therapeutic scope to include multiple autoimmune conditions.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Germany’s Boehringer Ingelheim (BI) has entered into a strategic agreement with US-based Cue Biopharma, Inc….<\/p>\n","protected":false},"author":1,"featured_media":31822,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[65,390,3999,4000],"class_list":["post-31820","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-auto-immune","tag-boehringer-ingelheim","tag-cue-biopharma","tag-nasdaq-cue"],"yoast_head":"\nBoehringer Ingelheim Partners with Cue Biopharma to Advance CUE-501 for Autoimmune Diseases - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Germany's Boehringer Ingelheim (BI) has entered into a strategic agreement with US-based Cue Biopharma, Inc. (NASDAQ: CUE) to jointly develop and commercialize CUE-501, an innovative B cell depletion therapy for autoimmune diseases. This collaboration aims to advance a novel therapeutic approach that selectively targets B cells while engaging virus-specific memory killer T cells, potentially offering improved efficacy and safety.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=31820\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Boehringer Ingelheim Partners with Cue Biopharma to Advance CUE-501 for Autoimmune Diseases\" \/>\n<meta property=\"og:description\" content=\"Germany's Boehringer Ingelheim (BI) has entered into a strategic agreement with US-based Cue Biopharma, Inc. (NASDAQ: CUE) to jointly develop and commercialize CUE-501, an innovative B cell depletion therapy for autoimmune diseases. This collaboration aims to advance a novel therapeutic approach that selectively targets B cells while engaging virus-specific memory killer T cells, potentially offering improved efficacy and safety.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=31820\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-15T05:44:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-15T05:44:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1506-png.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31820#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31820\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Boehringer Ingelheim Partners with Cue Biopharma to Advance CUE-501 for Autoimmune Diseases\",\"datePublished\":\"2025-04-15T05:44:54+00:00\",\"dateModified\":\"2025-04-15T05:44:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31820\"},\"wordCount\":209,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31820#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1506-png.webp\",\"keywords\":[\"Auto-immune\",\"Boehringer Ingelheim\",\"Cue Biopharma\",\"NASDAQ: CUE\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31820#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31820\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=31820\",\"name\":\"Boehringer Ingelheim Partners with Cue Biopharma to Advance CUE-501 for Autoimmune Diseases - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31820#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31820#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1506-png.webp\",\"datePublished\":\"2025-04-15T05:44:54+00:00\",\"dateModified\":\"2025-04-15T05:44:55+00:00\",\"description\":\"Germany's Boehringer Ingelheim (BI) has entered into a strategic agreement with US-based Cue Biopharma, Inc. (NASDAQ: CUE) to jointly develop and commercialize CUE-501, an innovative B cell depletion therapy for autoimmune diseases. This collaboration aims to advance a novel therapeutic approach that selectively targets B cells while engaging virus-specific memory killer T cells, potentially offering improved efficacy and safety.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31820#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31820\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31820#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1506-png.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1506-png.webp\",\"width\":1080,\"height\":608,\"caption\":\"Boehringer Ingelheim Partners with Cue Biopharma to Advance CUE-501 for Autoimmune Diseases\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31820#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Boehringer Ingelheim Partners with Cue Biopharma to Advance CUE-501 for Autoimmune Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Boehringer Ingelheim Partners with Cue Biopharma to Advance CUE-501 for Autoimmune Diseases - Insight, China's Pharmaceutical Industry","description":"Germany's Boehringer Ingelheim (BI) has entered into a strategic agreement with US-based Cue Biopharma, Inc. (NASDAQ: CUE) to jointly develop and commercialize CUE-501, an innovative B cell depletion therapy for autoimmune diseases. This collaboration aims to advance a novel therapeutic approach that selectively targets B cells while engaging virus-specific memory killer T cells, potentially offering improved efficacy and safety.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=31820","og_locale":"en_US","og_type":"article","og_title":"Boehringer Ingelheim Partners with Cue Biopharma to Advance CUE-501 for Autoimmune Diseases","og_description":"Germany's Boehringer Ingelheim (BI) has entered into a strategic agreement with US-based Cue Biopharma, Inc. (NASDAQ: CUE) to jointly develop and commercialize CUE-501, an innovative B cell depletion therapy for autoimmune diseases. This collaboration aims to advance a novel therapeutic approach that selectively targets B cells while engaging virus-specific memory killer T cells, potentially offering improved efficacy and safety.","og_url":"https:\/\/flcube.com\/?p=31820","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-15T05:44:54+00:00","article_modified_time":"2025-04-15T05:44:55+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1506-png.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=31820#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=31820"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Boehringer Ingelheim Partners with Cue Biopharma to Advance CUE-501 for Autoimmune Diseases","datePublished":"2025-04-15T05:44:54+00:00","dateModified":"2025-04-15T05:44:55+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=31820"},"wordCount":209,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=31820#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1506-png.webp","keywords":["Auto-immune","Boehringer Ingelheim","Cue Biopharma","NASDAQ: CUE"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=31820#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=31820","url":"https:\/\/flcube.com\/?p=31820","name":"Boehringer Ingelheim Partners with Cue Biopharma to Advance CUE-501 for Autoimmune Diseases - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=31820#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=31820#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1506-png.webp","datePublished":"2025-04-15T05:44:54+00:00","dateModified":"2025-04-15T05:44:55+00:00","description":"Germany's Boehringer Ingelheim (BI) has entered into a strategic agreement with US-based Cue Biopharma, Inc. (NASDAQ: CUE) to jointly develop and commercialize CUE-501, an innovative B cell depletion therapy for autoimmune diseases. This collaboration aims to advance a novel therapeutic approach that selectively targets B cells while engaging virus-specific memory killer T cells, potentially offering improved efficacy and safety.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=31820#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=31820"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=31820#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1506-png.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1506-png.webp","width":1080,"height":608,"caption":"Boehringer Ingelheim Partners with Cue Biopharma to Advance CUE-501 for Autoimmune Diseases"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=31820#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Boehringer Ingelheim Partners with Cue Biopharma to Advance CUE-501 for Autoimmune Diseases"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1506-png.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31820","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=31820"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31820\/revisions"}],"predecessor-version":[{"id":31823,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31820\/revisions\/31823"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/31822"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=31820"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=31820"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=31820"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}